Abstract
The article examines the foundational principles of biomedical ethics and their relevance to the intersection of artificial intelligence (AI) and biotechnological progress. It then analyzes the potential impact of the National Institutes of Health’s (NIH or the Agency) proposed 2024 reorganization reforms, as presented by the House Committee on Energy and Commerce (E&C), and advocates for the inclusion of provisions that would enable the Agency to develop and deploy “safe, secure, and trustworthy” AI within the biotechnology sector. Thus, the article proposes two key integrative reforms to address these concerns: (1) enhancing research collaborations among healthcare systems, academic institutions, and the private sector through AI-driven platforms, and (2) establishing an NIH office to oversee AI-based health initiatives. These reforms would require legislative amendments, including updates to the Patent and Trademark Law Amendments Act of 1980 (Bayh-Dole Act or Bayh Dole) and the 21st Century Cures Act of 2016 (Cures Act), while adhering to biomedical ethics. Such amendments would ensure (1) ethical standards in collaborative research and development (R&D) among institutions and (2) effective health initiative design and implementation. In the same light, this article advocates for an updated legislative framework to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) that regulates the role of such integrative efforts and balances the transformative potential of AI in biotechnology. In all, these regulatory steps ensure that innovation benefits society while safeguarding individual rights such as personal data and privacy and mitigating algorithmic bias.
Get full access to this article
View all access options for this article.